References
- Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013 Oct 10;155(2):462–477.
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231–1251.
- Eskilsson E, Rosland GV, Solecki G, et al. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro Oncol. 2018 May 18;20(6):743–752.
- Chi AS, Cahill DP, Reardon DA, et al. Exploring predictors of response to dacomitinib in EGFR-amplified recurrent glioblastoma. JCO Precis Oncol. 2020 Jun 8;4:PO.19.00295.
- Sarkaria JN, Hu LS, Parney IF, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 2018 Jan 22;20(2):184–191.
- Kizilbash SH, Gupta SK, Parrish KE, et al. In Vivo Efficacy of tesevatinib in EGFR-amplified patient-derived xenograft glioblastoma models may be limited by tissue binding and compensatory signaling. Mol Cancer Ther. 2021 Jun;20(6):1009–1018.
- Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018; 28:JCO2018783118.
- Lin B, Ziebro J, Smithberger E, et al. EGFR, the Lazarus target for precision oncology in glioblastoma. Neuro Oncol. 2022 Sep 19. DOI:10.1093/neuonc/noac204.
- [cited 2022 Nov 1st] Available from: https://clinicaltrials.gov/ct2/show/results/NCT02844439?view=results
- Francis JM, Zhang CZ, Maire CL, et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014 Aug;4(8):956–971.
- Nathanson DA, Gini B, Mottahedeh J, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014 Jan 3;343(6166):72–76.
- Nicholson JG, Fine HA. Diffuse glioma heterogeneity and its therapeutic implications. Cancer Discov. 2021 Mar;11(3):575–590.
- An Z, Aksoy O, Zheng T, et al. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018 Mar;37(12):1561–1575.
- McKinney A, Lindberg OR, Engler JR, et al. Mechanisms of resistance to EGFR inhibition reveal metabolic vulnerabilities in human GBM. Mol Cancer Ther. 2019 Sep;18(9):1565–1576.
- Gan HK, Burgess AW, Clayton AH, et al. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res. 2012 Jun 15;72(12):2924–2930.